Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) on February 3, 2016. The report addresses a corporate governance event regarding the listing status of the Company's common stock on the NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the Market Value of Listed Securities (MVLS), which had closed below the $50,000,000 minimum requirement for the NASDAQ Global Select Market for 30 consecutive business days prior to September 29, 2015.
Material Changes
- Listing Transfer: The Company received approval to transfer its listing from the NASDAQ Global Select Market to the NASDAQ Capital Market, effective February 5, 2016.
- Compliance Status: The transfer resolves a deficiency notice regarding the MVLS requirement for the Global Select Market.
- Trading Symbol: The common stock will continue to trade under the symbol "ONTX."
Outlook, Risks, and Management Commentary
Management notes that while the transfer resolves the MVLS deficiency, the Company's stock price has recently traded below the minimum bid price required for the NASDAQ Capital Market. If the bid price does not increase in the near term, the Company expects to receive a new deficiency notice from the NASDAQ Capital Market. This would trigger a new 180-day compliance period, during which the Company will consider further options to maintain its listing.
Investor Verification Checklist
- Verify the current trading status and bid price of ONTX to assess the risk of a new deficiency notice.
- Confirm the effective date of the listing transfer (February 5, 2016).
- Review the attached press release (Exhibit 99.1) for additional details on the listing approval.
- Monitor future filings for updates on compliance with NASDAQ Capital Market bid price requirements.